As the United States prepares to honor its military veterans on Monday, medtech researchers are working to help survivors wounded in battle, both in body and mind. Whether the research comes out of government, industry or academia, there’s also a desire to help veterans facing other health challenges. Get the full story on our sister […]
Regenerative Medicine
Admedus deals biologic patch business to LeMaitre Vascular for $24m
Admedus (ASX:AHZ) dealt its biologic patch business to LeMaitre Vascular (NSDQ:LMAT) in a deal worth up to $24.6 million to focus on the transcatheter aortic valve replacement market. The A$36.2 million buyout of the CardioCel and VascuCel patches called for LeMaitre to put up $14.2 million up front, with another $1.4 million due in a pair […]
BioCardia wins CE Mark renewal for Helix, Morph catheters
BioCardia (OTC:BCDA) said yesterday that it won CE Mark renewal for its Helix biotherapeutic delivery catheter and Morph universal deflectable guide catheter for delivery of biotherapeutics to the heart. With the renewed CE Mark, BioCardia said it can continue supporting partners outside the U.S. and move forward with commercial sales of the Helix and Morph systems […]
Imbed Biosciences wins $1.5m NIH grant
Imbed Biosciences said last week that it received a $1.5 million grant from the National Institutes of Health to develop a bioresorbable, antibacterial wound dressing. Fitchburg, Wis.-based Imbed said the two-year Small Business Innovation Research grant, from the NIH’s National Institute for Arthritis & Musculoskeletal & Skin Diseases, is for R&D on a bioresorbable wound […]
Medtronic announces Infuse spine trial
Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, […]
Frequency Therapeutics registers $100m IPO
Frequency Therapeutics has registered an initial public offering of common stock worth $100 million. Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units. The company applied to the Securities and Exchange Commission have its common stock listed on The Nasdaq Global Market […]
AxoSim touts results of nerve-on-a-chip study
A new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders. The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. These […]
Celling Spine acquires Link Spine
Celling Biosciences subsidiary Celling Spine said today that it acquired the Link Spine assets from Link Orthopedics for an undisclosed amount. Austin, Texas-based Celling Spine said it plans to develop a “biologically enhanced” spinal fusion system using its in-house cell-based biologics and the Link Spine fusion system. “We have always maintained that the future of […]
MiMedx: Ex-managers cooked the books, went after whistleblowers
The former management team at MiMedx (NSDQ:MDXG), led by ex-CEO Parker Petit, allegedly enacted a scheme to cook the books at the regenerative medicine company, retaliated against anyone who questioned their sketchy accounting practices and secretly filmed their offices, according to a probe the company launched after the scheme blew up last year. In February 2018, […]
Report: Vericel to supply Epicel-based grafts for baby born without skin
Vericel (NSDQ:VCEL) is growing skin grafts using its Epicel product to help a baby born in Texas without skin, according to a recent Boston Business Journal report. The company said yesterday that it is creating grafts with its Epicel skin replacement product for newborn Ja’bari Gray, who has been in intensive care since being born earlier […]
Histogenics completes transformation into Ocugen with $7m deal for NeoCart
UPDATED May 14, 2019, with comment from Medavate. Histogenics (NSDQ:HSGX) said today that it completed another step on its transformation into clinical-stage biopharmaceutical company Ocugen, with a nearly $7 million deal to sell its NeoCart regenerative knee treatment to Medavate. The $6.5 million all-cash deal, signed May 8, will see all of the NeoCart assets pass […]
